Evidence map›Paper›PMID 34573242›Full record

ArticleBrain sciences2021

Cognitive Function during the Prodromal Stage of Alzheimer's Disease in Down Syndrome: Comparing Models.

Christy L Hom, Katharine A Kirby, Joni Ricks-Oddie, David B Keator, Sharon J Krinsky-McHale, Margaret B Pulsifer, Herminia Diana Rosas, Florence Lai, Nicole Schupf, Ira T Lott and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Early Markers for Dementia in the Intellectual Disability Population: A Systematic Literature Review.Journal of applied research in intellectual disabilities : JARID · 2025
    Pooled it
  2. Symptoms and age of prodromal Alzheimer's disease in Down syndrome: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  3. Review
  4. Article
  5. Alzheimer's Disease Research Center Down Syndrome Cores: Experience from two sites.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  6. Review
  7. Article
  8. The Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS): A 10-year report.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Christy L HomDepartment of Psychiatry and Human Behavior, University of California, Orange, CA 92868, USA.ORCID 0000-0003-0266-0961
Katharine A KirbyCenter for Statistical Consulting, University of California, Irvine, CA 92697, USA.
Joni Ricks-OddieCenter for Statistical Consulting, University of California, Irvine, CA 92697, USA.
David B KeatorDepartment of Psychiatry and Human Behavior, University of California, Orange, CA 92868, USA.
Sharon J Krinsky-McHaleNew York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY 10314, USA.ORCID 0000-0002-7205-7319
Margaret B PulsiferDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Herminia Diana RosasDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Florence LaiDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Nicole SchupfDepartment of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10027, USA.
Ira T LottDepartment of Pediatrics, University of California, Orange, CA 92868, USA.
Wayne SilvermanDepartment of Pediatrics, University of California, Orange, CA 92868, USA.

Funding

Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HANDEN, BENJAMIN L · 2020 to 2025
$103.7M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Miguel Arce · 2020 to 2026
$30.1M
Biomarkers of Alzheimer's Disease in Adults with Down SyndromeU01AG051412 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LOTT, IRA T., SCHUPF, NICOLE · 2015 to 2019
$26.3M
NCATS NIH HHS UL1 TR001414NIA NIH HHS P30 AG066462NIA NIH HHS U01 AG051412NIA NIH HHS U19 AG068054
6 · The paper itself

Abstract

Accurate identification of the prodromal stage of Alzheimer's disease (AD), known as mild cognitive impairment (MCI), in adults with Down syndrome (MCI-DS) has been challenging because there are no established diagnostic criteria that can be applied for people with lifelong intellectual disabilities (ID). As such, the sequence of cognitive decline in adults with DS has been difficult to ascertain, and it is possible that domain constructs characterizing cognitive function in neurotypical adults do not generalize to this high-risk population. The present study examined associations among multiple measures of cognitive function in adults with DS, either prior to or during the prodromal stage of AD to determine, through multiple statistical techniques, the measures that reflected the same underlying domains of processing. Participants included 144 adults with DS 40-82 years of age, all enrolled in a larger, multidisciplinary study examining biomarkers of AD in adults with DS. All participants had mild or moderate lifelong intellectual disabilities. Overall AD-related clinical status was rated for each individual during a personalized consensus conference that considered performance as well as health status, with 103 participants considered cognitively stable (CS) and 41 to have MCI-DS. Analyses of 17 variables derived from 10 tests of cognition indicated that performance reflected three underlying factors: language/executive function, memory, and visuomotor. All three domain composite scores significantly predicted MCI-DS status. Based upon path modeling, the language/executive function composite score was the most affected by prodromal AD. However, based upon structural equation modeling, tests assessing the latent construct of memory were the most impacted, followed by those assessing visuomotor, and then those assessing language/executive function. Our study provides clear evidence that cognitive functioning in older adults with DS can be characterized at the cognitive domain level, but the statistical methods selected and the inclusion or exclusion of certain covariates may lead to different conclusions. Best practice requires investigators to understand the internal structure of their variables and to provide evidence that their variables assess their intended constructs.

Indexed as

Alzheimer’s diseasecognitive declinecognitive functionDown syndromemild cognitive impairmentneuropsychological tests

Identifiers

PMID34573242
PMCPMC8471085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.